Issues

Triple negative breast cancer (TNBC) is highly aggressive and is characterized by poor prognosis and increased risk of visceral metastases. On the cover, Deng and colleagues demonstrate the efficacy of a colchicine binding site inhibitor, VERU-111, on tubulin in TNBC cells. VERU-111 showed potent cytotoxicity against TNBC in vitro. In vivo, orally administered VERU-111 effectively inhibited the tumor growth in two aggressive TNBC xenograft models, including a taxane-resistant PDX model. VERU-111 significantly repressed visceral metastasis in both xenograft models and in an experimental metastasis model, suggesting VERU-111 is a promising drug candidate for the treatment of metastatic TNBC, potentially including patients who progress on taxanes. Read the article on page 348.